Skip Ribbon Commands Skip to main content
Sanofi
Share This

Recombitek® Equine WNV

hdr

Recombitek® Equine West Nile Virus
West Nile Virus Vaccine, Live Canarypox Vector

Logo

DESCRIPTION

RECOMBITEK® Equine West Nile Virus contains a lyophilized recombinant canarypox vectored West Nile Virus vaccine plus a sterile liquid diluent. A canarypox vector has been modified using recombinant technology to express the desired antigens capable of stimulating a protective immune response to West Nile Virus. After inoculation, the vector does not multiply in the horse, but does express the protective proteins. As a consequence, these components induce an immune status against West Nile Virus. Safety and immunogenicity of this vaccine have been demonstrated by vaccination and challenge tests in susceptible horses.

INDICATIONS

RECOMBITEK® WNV is recommended for the vaccination of healthy horses as an aid in the prevention of viremia due to West Nile Virus infection.

DOSAGE

Reconstitute the lyophilized vaccine with accompanying liquid diluent and aseptically inject a 1 mL dose by intramuscular route. For primary vaccination, revaccinate with a second 1 mL dose of this product 4 to 6 weeks later. Annual revaccination with a single dose is recommended.

PRECAUTIONS

Store at 2-7 ° C (35-45 ° F). For the preparation and administration of the vaccine, use sterile and antiseptic-free and/or disinfectant-free material. Burn container and all unused contents. Contains gentamicin as a preservative. Do not vaccinate within 21 days prior to slaughter. As with any vaccine, a hypersensitivity reaction may occur, which may require appropriate symptomatic treatment.

Sold to veterinarians only.

©2014